Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis

Pimavanserin is a selective 5-HT2A inverse agonist/antagonist approved for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Results from short-term, placebo-controlled studies demonstrated a positive benefit/risk profile. This multi-year, open-label study assessed long-term safety and tolerability of pimavanserin.

Source: Parkinsonism and Related Disorders - June 27, 2020 Category: Neurology Authors: Clive G. Ballard, David L. Kreitzman, Stuart Isaacson, I-Yuan Liu, James C. Norton, George Demos, Hubert H. Fernandez, Tihomir V. Ilic, Jean-Philippe Azulay, Joaquim J. Ferreira, Victor Abler, Srdjan Stankovic, for the 015 Study Group Source Type: research